Key eligibility: Requires tumor tissue progression on ADT or post-orchiectomy; no prior treatment for MCRPC; > 4 weeks since surgery, radiation; no prior enzalutamide, rucaparib or any PARP inhibitor or platinum chemo.
Note: This trial was temporarily suspended on April 10, 2023.
» Learn more about this trial
